The emerging role of tiotropium for patients with asthma;La función emergente del tiotropio en pacientes con asma

Annals of Pharmacotherapy

Volumn 47, Issue 5, 2013, Pages 704-713

  Bollmeier, Suzanne Gielow ^a   Lee, Shin Yu ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; IPRATROPIUM BROMIDE; MONTELUKAST; PLACEBO; PREDNISONE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ARTICLE; ASTHMA; CARDIOVASCULAR RISK; CLINICAL STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; NEUTROPHIL; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

EID: 84877096116     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R641     Document Type: Article

References (27)

1. Food and Drug Administration. FDA drug safety communication: new safety requirements for long-acting beta-agonists (LABAs). http://www. fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm200776.htm (accessed 2012 Aug 6).
2. Brozek JL, Kraft M, Krishnan JA, et al. Long-acting 22-agonist step-off in patients with controlled asthma. Systematic review with meta-analysis. Arch Intern Med 2012;172:1363-73.
3. Hizawa N. Beta-2 adrenergic receptor genetic polymorphisms and asthma. J Clin Pharm Ther 2009;34:631-43.
4. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Resp Res 2006;7:73. doi: 10.1186/1465-9921-7-73
5. Fryer AD, Jacoby DB. Muscarinic receptors and control of airway smooth muscle. Am J Resp Crit Care Med 1998;158:S154-60.
6. Terzano C, Petroianni A, Ricci A, D'Antoni L, Allegra L. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci 2004;8:259-64.
7. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr Op Pulm Med 2008;12:60-7.
8. Scullion JE. The development of anticholinergics in the management of COPD. Int J COPD 2007;2:33-40.
9. Expert Panel Report 3 (EPR3): guidelines for the diagnosis and management of asthma. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (accessed 2012 Aug 8).
10. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. J Respir Crit Care Med 1996;154:876-80.
11. Fardon T, Haggart K, Lee DKC, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007;101:1218-29.
12. Measurement of health-related quality of life and asthma control. http://qoltech.co.uk/miniaqlq.html (accessed 2012 Oct 28).
13. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715-26.
14. Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol 2012;129:S65-87.
15. Iwamoto H, Yokoyama A, Shiota N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008;31:1379-82.
16. Kapoor AS, Olsen SR, O'Hara C, Puttagunta L, Vethanayagam D. The efficacy of tiotropium as a steroid-sparing agent in severe asthma. Can Respir J 2009;3:99-101.
17. Kerstjens HAM, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011;128:308-14.
18. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367: 1198-207.
19. Bell EH. Tiotropium for asthma-promise and caution. N Engl J Med 2012;367:1257-9.
20. Tattersfield AE, Hall IP. Are beta 2-adrenoceptor polymorphisms important in asthma-an unravelling story. Lancet 2004;364:1464-6.
21. Hall IP, Sayer I. Pharmacogenetics and asthma: false hope or new dawn? Eur Respir J 2007;29:1239-45.
22. Metzger NL, Kochler DR, Gravatt LAH. Confirmed 216-ARG/ARG polymorphism in a patient with uncontrolled asthma. Ann Pharmacother 2008;42:874-81. doi: 10.1345/aph.1K682
23. Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009;64:778-83.
24. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in l16-ARG/ARG patients with asthma. J Allergy Clin Immunol 2011;128:315-22.
25. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA's conclusions. N Engl J Med 2010;363:1097-9.
26. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008;300:1439-50.
27. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovas-cular safety of tiotropium in patients with COPD. Chest 2010;137:20-30.